Mathew A Rank

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Improving the safety of immunotherapy
    Matthew A Rank
    Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz Electronic address
    J Allergy Clin Immunol Pract 2:131-5. 2014
  2. pmc A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations: data from a pilot study
    Matthew A Rank
    Division of Allergy, Asthma, and Immunology, Mayo Clinic, Scottsdale, Arizona, USA
    Am J Rhinol Allergy 27:98-101. 2013
  3. doi request reprint Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program
    Matthew A Rank
    Division of Allergy, Asthma, and Immunology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Ann Allergy Asthma Immunol 110:354-358.e2. 2013
  4. doi request reprint The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, MN 55905, USA
    J Allergy Clin Immunol 131:724-9. 2013
  5. ncbi request reprint Asthma expenditures in the United States comparing 2004 to 2006 and 1996 to 1998
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA
    Am J Manag Care 18:499-504. 2012
  6. doi request reprint Pretests or advance organizers for Web-based allergy-immunology medical education? A randomized controlled trial
    Matthew A Rank
    Department of Internal Medicine, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA
    Allergy Asthma Proc 33:191-6. 2012
  7. doi request reprint The impact of asthma medication guidelines on asthma controller use and on asthma exacerbation rates comparing 1997-1998 and 2004-2005
    Matthew A Rank
    Division of Allergic Diseases, Olmsted Medical Center, Rochester, MN, USA
    Ann Allergy Asthma Immunol 108:9-13. 2012
  8. pmc Trigger recognition and management in poorly controlled asthmatics
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Allergy Asthma Proc 31:99-105. 2010
  9. doi request reprint Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors
    Mathew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Allergy Asthma Proc 29:400-5. 2008
  10. ncbi request reprint A 38-year-old woman with dyspnea and wheezing following exercise despite asthma therapy
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Chest 132:351-3. 2007

Detail Information

Publications10

  1. ncbi request reprint Improving the safety of immunotherapy
    Matthew A Rank
    Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz Electronic address
    J Allergy Clin Immunol Pract 2:131-5. 2014
    ..Finally, we highlight the key knowledge gaps identified in this review and provide management recommendations for this 42-year-old woman. ..
  2. pmc A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations: data from a pilot study
    Matthew A Rank
    Division of Allergy, Asthma, and Immunology, Mayo Clinic, Scottsdale, Arizona, USA
    Am J Rhinol Allergy 27:98-101. 2013
    ..One way to gain insight into the pathophysiology of chronic rhinosinusitis (CRS) is to study the immunologic changes that occur with exacerbation. This study describes the immunologic changes during CRS exacerbation..
  3. doi request reprint Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program
    Matthew A Rank
    Division of Allergy, Asthma, and Immunology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Ann Allergy Asthma Immunol 110:354-358.e2. 2013
    ..Little is known about outcomes after stepping down asthma medications within an asthma management program...
  4. doi request reprint The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, MN 55905, USA
    J Allergy Clin Immunol 131:724-9. 2013
    ..Current asthma guidelines suggest that patients and their providers consider decreasing or stopping controller medications when asthma is stable...
  5. ncbi request reprint Asthma expenditures in the United States comparing 2004 to 2006 and 1996 to 1998
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA
    Am J Manag Care 18:499-504. 2012
    ..To describe how the types of healthcare expenditures for patients with asthma have changed over the past decade...
  6. doi request reprint Pretests or advance organizers for Web-based allergy-immunology medical education? A randomized controlled trial
    Matthew A Rank
    Department of Internal Medicine, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA
    Allergy Asthma Proc 33:191-6. 2012
    ..0001). Introducing Web-based allergy education with PT questions or an AO resulted in similar posttest scores. Posttest scores in the PT group improved significantly compared with PT scores...
  7. doi request reprint The impact of asthma medication guidelines on asthma controller use and on asthma exacerbation rates comparing 1997-1998 and 2004-2005
    Matthew A Rank
    Division of Allergic Diseases, Olmsted Medical Center, Rochester, MN, USA
    Ann Allergy Asthma Immunol 108:9-13. 2012
    ..The relationship between asthma controller medication use and exacerbation rates over time is unclear at the population level...
  8. pmc Trigger recognition and management in poorly controlled asthmatics
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Allergy Asthma Proc 31:99-105. 2010
    ..Future interventions for improving asthma trigger management should be targeted to routine asthma outpatient visits, where trigger avoidance advice is infrequent and rarely addressed in follow-up visits...
  9. doi request reprint Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors
    Mathew A Rank
    Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Allergy Asthma Proc 29:400-5. 2008
    ..However, a high percentage of SRs occurred >30 minutes after the injection, and many of these SRs required epinephrine. This study was unable to identify specific risk factors that predict SRs to AIT...
  10. ncbi request reprint A 38-year-old woman with dyspnea and wheezing following exercise despite asthma therapy
    Matthew A Rank
    Division of Allergic Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Chest 132:351-3. 2007